## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

## 1. (Currently Amended) A compound of formula I:

$$R^{8}$$
 $R^{9}$ 
 $R^{9}$ 
 $R^{10}$ 
 $R^{10}$ 

wherein:

X is CHC( $R^{13}Y'Y$ ), or  $CR^{6'}R^{6}$ , S,  $NR^{6}$ , or O;

R<sup>2</sup>, R<sup>4</sup>, R<sup>4</sup>, R<sup>7</sup> and R<sup>7</sup> are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

R<sup>2</sup>, R<sup>3</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> are each hydrogen or a pro-drug moiety;

R<sup>4</sup> is NR<sup>4</sup>'R<sup>4</sup>", alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;

R<sup>5</sup> is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

R<sup>6</sup> and R<sup>6</sup> are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R<sup>8</sup> is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R<sup>9</sup> is aminoalkyl;

R<sup>13</sup> is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.

2. (Original) The compound of claim 1, wherein  $R^4$  is  $NR^4R^4$ , X is  $CR^6R^6$ ;  $R^2$ ,  $R^2$ ,  $R^5$ ,  $R^6$ ,  $R^6$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are each hydrogen; and,  $R^4$ ,  $R^4$ ,  $R^4$ ,  $R^7$ , and  $R^7$  are each lower alkyl.

- 3. (Original) The compound of claim 2, wherein  $R^{4'}$ ,  $R^{4''}$ ,  $R^{7'}$ , and  $R^{7''}$  are each methyl.
- 4. (Original) The compound of claim 3, wherein said aminoalkyl is aminomethyl.
- 5. (Original) The compound of claim 3 or 4, wherein said aminoalkyl is substituted with an alkyl group.
- 6. **(Original)** The compound of claim 5, wherein said alkyl group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl.
- 7. (Original) The compound of claim 6, wherein said alkyl group is a branched chain alkyl group.
- 8. (Original) The compound of claim 5, wherein said alkyl group is n-pentyl.
- 9. (Original) The compound of claim 5, wherein said alkyl group has six carbon atoms or fewer.
- 10. (Original) The compound of claim 5, wherein said alkyl group is unsubstituted.
- 11. (Original) The compound of claim 5, wherein said alkyl group is substituted.
- 12. **(Original)** The compound of claim 11, wherein said alkyl group is substituted with alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
- 13. **(Original)** The compound of claim 3, wherein said aminoalkyl is substituted with two alkyl groups.

Application No.: 10/786,881 Docket No.: PAZ-222CN Examiner: S. N. Qazi Art Unit: 1616

14. (Original) The compound of claim 5, wherein said compound is selected from the group consisting of:

or pharmaceutically acceptable salts, esters and prodrugs thereof.

15. (Previously Presented) The compound of claim 1, wherein said compound is

or pharmaceutically acceptable salts, esters and prodrugs thereof.

16. (Original) The compound of claim 3, wherein said aminoalkyl is of the formula  $-CH_2NR^{9c}C(=Z')ZR^{9a}$ ,

wherein

Z is CR<sup>9d</sup>R<sup>9e</sup>, S, NR<sup>9b</sup> or O; Z' is NR<sup>9f</sup>, O or S; and

R<sup>9a</sup>, R<sup>9b</sup>, R<sup>9c</sup>, R<sup>9e</sup> and R<sup>9f</sup> are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;


- 17. (Original) The compound of claim 16, wherein R<sup>9c</sup> is hydrogen.
- 18. (Original) The compound of claim 16, wherein Z' is S, NH, or O.
- 19. (Original) The compound of claim 16, wherein Z is NR<sup>9b</sup>, O or S.
- 20. (Original) The compound of claim 19, wherein R<sup>9b</sup> is hydrogen or alkyl.

21. (Original) The compound of claim 16, wherein  $R^{9a}$  is an aryl group.

- 22. **(Original)** The compound of claim 21, wherein R<sup>9a</sup> is unsubstituted phenyl, *para*tolyl, *para*-nitrophenyl, *para*-methoxy phenyl, *para*-dimethylamino phenyl, *para*-perfluoromethoxy phenyl, *para*-acetyl phenyl, benzodioxole, 3,5-diperfluoromethyl phenyl, *para*-bromo phenyl, *para*-chloro phenyl, or *para*-fluoro phenyl.
- 23. (Original) The compound of claim 21, wherein  $R^{9a}$  is a heterocycle.
- 24. (Original) The compound of claim 16, wherein R<sup>9a</sup> is substituted or unsubstituted alkyl.
- 25. (Original) The compound of claim 16, wherein R<sup>9a</sup> is substituted or unsubstituted alkenyl.
- 26. (Currently Amended) The compound of claim 16, wherein said compound is selected from the group consisting of:

Application No.: 10/786,881

Examiner: S. N. Qazi Art Unit: 1616 Docket No.: PAZ-222CN



## 27-37. (Cancelled)

- 38. (Withdrawn-Currently Amended) A method for treating a tetracycline responsive state in a mammal, comprising administering to said subject a compound of claim 1, 15, 27, or 36, such that said subject is treated.
- The method of claim 38, wherein said tetracycline responsive state 39. (Withdrawn) is a bacterial infection.
- The method of claim 39, wherein said bacterial infection is 40. (Withdrawn) associated with gram positive bacteria.
- (Withdrawn) The method of claim 39, wherein said bacterial infection is 41. associated with gram negative bacteria.
- The method of claim 39, wherein said bacterial infection is 42. (Withdrawn) associated with E. coli.
- The method of claim 39, wherein said bacterial infection is 43. (Withdrawn) associated with S. aureus.
- The method of claim 39, wherein said bacterial infection is 44. (Withdrawn) associated with E. faecalis.

45. **(Withdrawn)** The method of claim 39, wherein said bacterial infection is resistant to other tetracycline antibiotics.

- 46. **(Withdrawn)** The method of claim 38, wherein said compound is administered with a pharmaceutically acceptable carrier.
- 47. (Withdrawn) The method of claim 38, wherein said subject is a human.
- 48. **(Withdrawn-Currently Amended)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claims 1, 15, 27, or 36 and a pharmaceutically acceptable carrier.